Skip to content
← Full study record

NCT04579757 · MORE INFO

Limitations, agreements, and source contact

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors · Source last updated 2025-05-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
false
restrictive Agreement
true
limitations And Caveats
description
The study was terminated based on the strategic re-evaluation of the clinical development of surufatinib in the United States and Europe with no safety concerns.
point Of Contact
email
nicolam@hutch-med.com
organization
HUTCHMED Limited
phone
+44 7738 881999
title
Nicky Murray
Complete source fields
certain Agreement
pi Sponsor Employee
false
restrictive Agreement
true
limitations And Caveats
description
The study was terminated based on the strategic re-evaluation of the clinical development of surufatinib in the United States and Europe with no safety concerns.
point Of Contact
email
nicolam@hutch-med.com
organization
HUTCHMED Limited
phone
+44 7738 881999
title
Nicky Murray

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice